Press Release – New scientific publication underpins Longboat’s Business Model (English version)
Recently a peer reviewed article was published in Stem Cell Research & Therapy (see link below) that underpins the intended business model of Longboat Explorers AB. The article concludes that Mesenchymal Stem Cells (sometimes also referred to as Mesenchymal Stromal Cells) are highly interesting for research and development in many of areas in regenerative medicine, but that this development is inhibited by the scarce availability of these stem cells. The most common sources of Mesenchymal Stem Cells today are bone marrow and adipose tissue (fatty tissue) from adult donors, whose stem cells are not of the same quality as those who come from fetal origin or newborns. There is one significant source of these high-quality neonatal stem cells today in cord blood from newborn infants, but the problem is that this source yields very few Mesenchymal Stem Cells per donor. As the scientific article suggests, by extracting Mesenchymal Stem Cells from amniotic fluid from women undergoing a C-section, a fluid that otherwise a waste product, one can score both a high yield of cells and produce mesenchymal stem cells of a very high neonatal quality.
Longboat Explorers AB is a Lund based biotech company with serial entrepreneur Christer Fåhraeus as partner and chairman. Longboat intends to put into practice what the article suggests and make more high quality neonatal Mesenchymal Stem Cells available for therapeutic development by applying a patent protected “eco system” for the extraction and expansion of the cell material from amniotic fluid.
Stem Cells are immature cells that through cell division can create cells of several different types of tissue. Mesenchymal Stem Cells can e.g. produce cells able to regenerate tissue of bone, cartilage, muscles and fat, which could be applicable in a wide array of degenerative diseases.
For further inquiry into this topic, please contact the CEO of Longboat, Anders Månsson (email@example.com) or the company’s CSO, Niels-Bjarne Woods (firstname.lastname@example.org) who is also a contributing author of the article below:
Scientific Publication: https://stemcellres.biomedcentral.com/articles/10.1186/s13287-017-0582-6
CEO, Longboat Explorers AB
Scheelevägen 2, 223 63 Lund, Sweden
Tel. +46 723 278 560